Glycerolipid metabolism

Glycerolipid metabolism encompasses the biochemical pathways responsible for the synthesis and degradation of lipids containing a glycerol backbone, primarily triglycerides, diglycerides, and monoglycerides. This pathway is a critical component of energy homeostasis, facilitating the storage of excess calories in adipose tissue and the mobilization of fatty acids during periods of energy deficit [1][2]. It also provides essential precursors for the synthesis of phospholipids, which are vital for maintaining the structural integrity of cellular membranes. In organs like the liver and intestine, glycerolipid metabolism is intricately linked to the assembly and secretion of lipoproteins, which transport neutral lipids through the circulatory system [3][4]. Abnormalities in glycerolipid metabolism are central to the development of metabolic syndrome, contributing significantly to the pathogenesis of obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD) [5]. Excessive accumulation of glycerolipids in non-adipose tissues, such as the liver and skeletal muscle, can lead to lipotoxicity and impaired insulin signaling. Therapeutic targeting of this pathway often involves inhibiting specific rate-limiting enzymes, such as diacylglycerol O-acyltransferase (DGAT) or lipases, to reduce triglyceride levels and mitigate cardiovascular risk [6]. While 'Glycerolipid metabolism' is a broad metabolic process rather than a single molecular target, it serves as the framework for numerous drug development strategies aimed at correcting dyslipidemia and improving metabolic health [1][6]. Sources: [1] KEGG Pathway: Glycerolipid metabolism - map00561. [2] NIH: The biology of lipid droplets and their role in glycerolipid metabolism. [3] PubMed: Regulation of glycerolipid metabolism in the liver (PMID: 25447761). [4] UniProt: Biological process GO:0006641. [5] StatPearls: Physiology, Triglycerides. [6] Nature Reviews Drug Discovery: Targeting lipid metabolism in disease.

Other names

Glycerolipid metabolic processTriglyceride metabolismNeutral lipid metabolism

Pharmacological agents typically modulate this pathway by inhibiting specific enzymes such as pancreatic lipases to prevent fat absorption, or by targeting intracellular enzymes like diacylglycerol O-acyltransferases (DGAT) to reduce triglyceride synthesis. Other agents act as agonists for nuclear receptors like PPAR-alpha to increase fatty acid oxidation and clear triglycerides from the blood.